ITBMed Raises $67M To Induce Organ Transplant Tolerance

Swedish biopharma ITBMed has secured $67m to develop siplizumab, its anti-CD2 monoclonal antibody, as an alternative to life-long use of conventional immunosupressants in organ transplant patients.